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Abstract
For the first time, the WHO classification of brain tumors has introduced molecular 
parameters in the diagnosis of brain tumors. Together with embryonal tumors, the dif-
fuse gliomas have suffered significant changes in diagnosis, prognosis, and response to 
treatment. A new concept of “integrated diagnosis” comes to combine the classical diag-
nosis with the molecular one. While it is still impossible to disregard the histopathologi-
cal component, according to the new rule (“molecular beats histology”) makes molecular 
parameters dominant in the final diagnosis. Currently, the diffuse gliomas (oligoden-
droglial or astrocytic) are nosologically closer than the astrocytomas with a diffuse 
growth pattern, and the astrocytomas with a more circumscribed growth pattern defined 
by the presence of the IDH mutation. The family tree was redefined by the presence of the 
IDH mutation and of the 1p/19q codeletion. The implementation of this new concept in 
clinical practice will improve patient management, as well as the design of clinical trials 
and experimental studies. This must also be seen as a model for diagnosis setting in the 
new molecular era.
Keywords: astrocytoma, oligodendroglioma, glioblastoma, IDH mutation, 1p/19q 
co-deletion, integrated diagnosis
1. Introduction
The introduction of the new classification represents the first step in the switch of paradigm 
in brain tumor management toward an individualized-based treatment from the, nowadays, 
evidence-based management. The classification of diffuse gliomas has undergone signifi-
cant changes following the introduction of molecular testing, the new WHO 2016 classifica-
tion introducing a new concept—integrated diagnosis [1]. The current update takes into 
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account both the phenotype and the genotype [2]. This was the preferred alternative, as it is 
currently impossible to resort only to the molecular parameters in the definition of tumoral 
entities [3]. The classification relies both on the morphological character (growth pattern) 
and on the definition of the genetic status by determining the presence of mutations in the 
IDH1 and IDH2 genes and of the 1p/19q codeletion [4]. According to WHO 2016, diffuse 
gliomas are lumped together, regardless of their histopathological aspect (astrocytomas or 
oligodendrogliomas) [5].
The recourse to an integrated diagnosis makes it possible to formulate a more precise diagno-
sis of the various entities and acknowledges the existence of new entities [6].
The introduction of molecular parameters comes to improve the clinical management of 
patients, defining entities which feature a similar prognosis. It also paves the way to the iden-
tification of new treatment methods aimed at the biological mechanisms common to this type 
of tumors [5]. The genetic information supplied by the Cancer Genome Atlas Research indicate 
that the supratentorial gliomas with a diffuse growth pattern can be categorized separately 
from the other brain tumors (Figure 1) [7]. They are grouped into three categories, according 
to the genetic profile—the presence or absence of the 1p/19q codeletion and the mutational 
status of the IDH gene. The first category includes the gliomas with a classical morphology 
of oligodendrogliomas, having both the IDH gene mutation and the 1p/19q codeletion. The 
second category is represented by the tumors with an astrocytic histological pattern and IDH 
mutation, but without the 1p/19q codeletion. In the third category, we find the tumors with 
an astrocytic phenotype, which display no IDH mutation or 1p/19q codeletion. The latter cat-
egory usually falls under the classical wild-type glioblastoma diagnosis [8].
Figure 1. Integrated diagnosis of astrocytic and oligodendroglial tumors.
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This approach separates between the astrocytomas with a circumscribed growth pattern, no 
IDH mutation, and with BRAF mutation (pilocytic astrocytoma, pleomorphic xantoastrocy-
toma, and subependymal giant cell astrocytoma), on the one hand, and the diffuse astrocytic 
and oligodendroglial tumors, on the other. According to the new classification, the diffuse 
astrocytic and oligodendroglial tumors are nosologically closer than the diffuse astrocytoma 
and the pilocytic astrocytoma [9].
The inclusion in these categories on the basis of genetic determinations also has a role in 
prognosis [10].
When there is a mismatch between the phenotype and the genotype, genetic tests set the final 
diagnosis in keeping with the rule “molecular beats histopathology [1].”
Glioblastoma with the IDH mutation show a better evolution than the wild-type ones, gener-
ally corresponding to a secondary glioblastoma. They also have a better prognosis than the 
wild-type anaplastic astrocytoma. The wild-type astrocytomas have the worst prognosis of all 
astrocytomas, their molecular profile being characteristic for glioblastomas (EGFR amplifica-
tions, PTEN mutation, and 10q, 9p loss) [11].
The introduction of molecular parameters in the definition of entities has led to the recog-
nition of a new entity in the group of diffuse pediatric gliomas: the tumors with a midline 
location, diffuse growth pattern, and the K27 M mutation in the H3 histone gene. This is 
the first attempt to distinguish between the pediatric brain tumors and their adult coun-
terparts, the difference in behavior between histopathologically identical tumors being 
long known [12].
As to the histological grading, the WHO 2016 classification keeps the three-tiered sys-
tem. The shift from low to high malignancy depends upon morphological parameters that 
reflect the emergence of new biological processes. The first malignancy criterion is repre-
sented by the variations in the size, shape, and color intensity of the nucleus (atypia with 
hyperchromasia) [13]. The proliferation is reflected in the presence of mitoses, which must 
be unequivocal, with no additional specifications in terms of number and morphology 
[14]. A significant proliferation typical for high-grade tumors is highlighted by the advent 
of necrosis and of the attempt to compensate for this hypoxia through the emergence of 
microvascular proliferation. According to this classification, the diffuse astrocytomas limited 
to cytological atypia are deemed to be grade II, while those with both anaplasia and mitotic 
activity are deemed to be anaplastic (grade III). The presence of mitoses must be seen in 
context as only one mitosis in a large section is not enough for a grade III. If we are dealing 
with a small biopsy, then the presence of a mitosis may be sufficient. Grade IV is reserved 
to those tumors that display necrosis and/or vascular proliferation. Microvascular prolifera-
tion is defined as the stratification of the endothelium, or the “glomeruloid” aspect. The 
necrosis can be of any type [15].
In the group of low-grade gliomas (II and III), the histopathological stratification features a 
significant interobserver variability, as also demonstrated by the considerable differences in 
terms of survival rates manifest within this group. The evaluation of molecular parameters 
can also be useful in the sense of defining groups that correlate better with the prognosis [16].
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Gliomatosis cerebri no longer exists as an entity, being considered rather a specific growth 
pattern. More research is needed in order to identify the biological substrate of this unusual 
invasive capacity [17].
2. Low-grade gliomas
2.1. Diffuse astrocytoma IDH-mutant (DA IDH-mut)
Definition. Tumoral proliferation which, from a histopathological point of view, shows an 
astrocytic phenotype with a diffuse growth pattern and IDH1 or IDH2 gene mutations.
As to grading, diffuse astrocytoma is deemed to be grade II (low-grade diffuse astrocytoma).
Clinically, the emergence of symptoms is usually insidious, as they precede the diagnosis by 
weeks months or sometimes years. Seizures are the symptom most likely to raise suspicions. 
There are studies underling the presence of the seizures at the debut in up to 80% of cases, 
approximately 50% presenting with uncontrollable seizures at the time of surgery. Factors 
predisposing to a poorer response to antiepileptic drugs are: partial seizure type, temporal 
location, and a longer seizure duration [18]. The most frequent location of those tumors is in 
the frontal lobe, followed by temporal and parietal lobe. Other associated symptoms could 
appear related to the location. Behavioral and personality changes, visual disturbances, apha-
sia, or agnosia are most frequently mentioned, meanwhile the increased intracranial pressure 
symptoms install later in the course of disease, related to the tumoral volumes and mass effect.
Imaging. MRI is the “golden standard” imagistic tool. For DA IDH-mut, the typical aspect is a 
homogeneous tumor with low signal intensity on T1-weighted images and a high intensity on 
T2-weighted sequences. This high T2 signal is rather related to edema, demyelination, or degenera-
tive changes than to cellular atypia. Fluid-attenuated inversion recovery (FLAIR) sequences are the 
most appropriate for defining the infiltrating tumor margins. Usually, astrocytomas are confined 
in the white matter, meanwhile the oligodendrogliomas are cortical-based tumor, but this differ-
ence is attenuated in the later stages (Figure 2). Cystic components are not infrequent and low 
contrast enhancement could be observed in 20% of cases without malignant transformation [19].
Figure 2. Axial T2W (a), FLAIR (b), and T1W + C (c) MRI examination of a patient with right insular DA IDH-mut 
(personal archive).
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Advanced MRI techniques such as diffusion-weighted imaging (DWI) and MRI spectroscopy will 
complete the anatomical information, while the functional MRI and diffusion tensor imaging 
(DTI) will offer important data for surgical planning. On DWI, DA IDH-mut presents a decrease 
cellularity and non-restricted diffusion. MRI Spectroscopy will reveal not only decreased N-acetyl-
aspartate (NAA) peak, medium choline peaks, absence of lactate peak, and increased myo-inosi-
tol [20], but is also able to detect IDH mutation trough oncometabolite 2-hydroxyglutarate (2HG) 
present in tumor cells [21]. MRI could also serve as a prognosis tool if is combined with IDH status. 
Just recently it was suggested that minimum apparent diffusion coefficient (ADCMIN) threshold of 0.9 × 10−3 mm2/s or less is associated with a worst prognosis especially when it is combined 
with IDH wild-type grade II diffuse astrocytomas [22]. DTI with tractography usually reveals a 
displacement rather than an infiltration or destruction of fiber tracts in DA IDH-mut tumors.
CT scan reveals a homogeneous lesion, poorly defined, with no contrast enhancement. This can be 
associated with cystic changes and calcifications that are more specific for oligodendrogliomas.
Macroscopy. In section, the tumor does not display clearly delineated limits, on account of its 
infiltrative growth pattern. We can see areas of soft consistency or firmer ones, granular areas, 
and cystic ones. Cystic changes can include sponge-like areas, consisting of cysts of various 
sizes that may have a gelatinous aspect. There can be only one large cysts, filled with liquid, 
and this is associated with the identification of gemistocytes during microscopy. The calcifica-
tions can be focal or diffuse, and in this case, the appearance is one of grittiness.
Histological diagnosis. Under the microscope, we see a diffuse tumoral proliferation consist-
ing of atypical fibrillary astrocytes. Hypercellularity is moderately increased, the tumor imper-
ceptibly blending with the surrounding normal structures. Cellular proliferation (star-shaped 
cells, with extensions) is situated on a fibrillary loose matrix which often forms microcystic 
structures. The main characteristic is the nuclear atypia, neoplastic astrocytes being based on 
the aspect of the nucleus. This is enlarged, hyperchromatic, and irregular in shape [23].
The differential diagnosis is performed with the help of reactive astrocytosis. The diagnosis can 
be done only on the basis of morphological criteria, but more often than not, this requires an 
extremely nuanced approach. The morphological criteria include a numerical increase, but 
especially the homogeneous aspect of the nuclei, as we are dealing with a clonal neoplastic 
proliferation. As opposed to neoplastic astrocytes, the reactive ones have a heterogeneous 
nuclear aspect, with nuclei of various sizes and with cytoplasm in variable quantities. The 
background of these nuclei is of normal or increased density in the case of tumoral prolif-
eration, and of decreased density in the case of reactive astrocytosis. Immunohistochemistry 
is extremely useful in distinguishing between reactive and tumoral astrocytes. As the IDH1 
mutation falls under the definition of this type of tumor, the antibody identifying the protein 
altered by the presence of the R132H mutation can be used. Also, the tumoral cells displaying 
the TP53 mutation can be identified through a recourse to the antibody [24].
Mitotic activity is low to absent, the presence of a mitosis in a large biopsy being compatible 
with the diagnosis. If a mitosis is present in the context of an important nuclear anaplasia 
within a small biopsy, then the diagnosis of anaplastic astrocytoma cannot be ruled out. The 
proliferation index determined by way of Ki-67 is under 4%. If there is a gemistocytic compo-
nent, the proliferation rate is significantly reduced [25].
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As we are dealing with low proliferation rate tumor, the changes induced by hypoxia, such as 
microvascular proliferation and necrosis, are absent.
Secondary structures (Sherer) such as perineuronal satellitosis, subpial infiltration, and peri-
vascular aggregation can also be present.
Other entities that need to be factored in for the differential diagnosis are: the normal brain, 
the demyelinating disease, anaplastic astrocytoma, oligodendroglioma, and pilocytic astro-
cytoma. In what concerns the diffuse pattern, the differential diagnosis must be done with 
lymphomas and small-cell carcinomas [26].
Gemistocytic astrocytoma is a variant of the grade II diffuse astrocytoma, characterized by the 
presence of more than 20% angular neoplastic astrocytes, with abundant eosinophilic cyto-
plasm. The nucleus is pushed toward the periphery, showing nucleoli and a dense chromatin. 
Electronic microscopy reveals the presence of numerous mitochondria and glial filaments, as 
also confirmed by the positive GFAP. A characteristic feature is the presence of the perivascu-
lar cuffing lymphocyte [27].
The classical morphopathological aspect is astrocytic, but an “oligodendroglioma-like” com-
ponent can be accepted in the absence of 1p/19q codeletion.
Immunohistochemically, the battery of antibodies that can be used includes: GFAP, vimen-
tin, IDH R132H, p53, ATRX, Olig2, and Ki67. GFAP and vimentin are positive, but of variable 
expression. The existence of an antibody that makes it possible to indirectly identify the R132H 
mutation, present in approximately 90% of tumors, is one way of identifying the tumor cells 
featuring this mutation. Another important antibody is ATRX, and the presence of the mutation 
leads to the loss of nuclear expression in the tumor cells. P53 can be used, as an intense nuclear 
expression is consistent with the presence of the TP53 mutation. Olig2 is nearly always present. 
As already indicated, Ki-67 can be used in assessing the proliferation index [28–31].
Genetic diagnosis. Integrated genomic analysis has made it possible to identify the IDH gene 
mutation in glioblastomas, leading to the “IDH era” in diffuse gliomas [32]. The sequencing of a 
large number of brain tumors has revealed the high incidence of the IDH gene mutation in low-
grade astrocytomas and oligodendrogliomas, suggesting that it might play a role in the early 
onset of such tumors [33]. The presence of this mutation is relevant for both diagnosis and prog-
nosis, its absence meaning a less favorable prognosis [34]. A study conducted on a large cohort 
has indicated a survival rate of 10.9 years for the diffuse astrocytomas with the IDH mutation 
[35]. The consequence-inducing mechanism involves the excessive production and the accumu-
lation of an oncometabolite—2 hydroxyglutarate [36]. This mutation leads to significant epigen-
etic changes and to changes in the regulation of the expression of differentiating factors [37]. 
More particularly, we witness a hypermethylation of the genome, generating tumors with the 
CpG island methylator phenotype (CIMP) [38]. This group of tumors shows a distinct biologi-
cal behavior, with epigenetic changes in the whole genome, by remodeling the methylome and 
reorganizing the transcriptome. This leads to the activation of key genetic programs and to the 
emergence of a cellular phenotype allowing for better survival rates. Also, the IDH allows for 
chromosomal aberrant interactions, with the activation of the oncogene expression [39].
ATRX encodes a chromatin-binding protein. The mutations of this gene are associated with epi-
genetic changes [40]. It also activates the alternative telomere lengthening mechanism, necessary 
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in the pathogenesis of diffuse gliomas [41]. Furthermore, ATRX deficiency can create a con-
text of generalized genetic instability which, when P53 is intact, can induce apoptosis. The 
occurrence of a P53 mutation alongside the ATRX one can allow tumor cells to survive [42]. 
This instability is reflected in the occurrence of low-level amplifications for other oncogenes, 
such as MYC and CCND2 [43]. The TP53 mutation is also present in nearly all IDH-mutant 
gemistocytic astrocytomas, in both gemistocytes and non-gemistocytes, indicating that gem-
istocytes are oncogenically non-reactive cells [44]. Quite interestingly, the presence of the 
ATRX mutation is mutually exclusive with the mutation of the gene that encodes the catalytic 
component of TERT telomerase. The mutations of the TERT gene are characteristic for oligo-
dendrogliomas and wild-type glioblastomas [45].
The methylation of the MGMT gene promoter is present in more than 50% of IDH-mutant 
astrocytomas, but the presence of this methylation is not correlated with the status of G-CIMP 
[46]. By definition, 1p/19q codeletion is absent (Figure 3).
The genetic profile of diffuse astrocytomas is different in children and in adults; so, we can 
talk of adult-type and pediatric-type diffuse astrocytomas. The genetic profile of pediatric 
tumors involves amplifications and rearrangements of the MYB gene, alterations of FGFR1, 
and mutations of BRAF (V600) and KRAS [47].
Figure 3. Integrated histological and molecular diagnosis of diffuse astrocytoma IDH-mutant grade II.
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There are two entities that increase the susceptibility to diffuse astrocytomas. Low-grade 
astrocytomas are usually diagnosed in patients with Ollier-type multiple enchondromatosis 
[48]. Also, those having the Li-Fraumeni syndrome are more likely to develop diffuse glio-
mas, but these are high-grade anaplastic astrocytomas and high-grade glioblastomas [49].
2.1.1. Multimodal treatment
2.1.1.1. Surgical treatment
In the last decade, a great switch was produced in the therapeutical management of DA. Since 
it was demonstrated that these tumors have an annual linear grow of 4 mm/year on diam-
eter [50], they are nowadays considered “infiltrating chronic disease that invades the central 
nervous system, that will ineluctably become malignant” [51]. It is now well established that 
surgery has a great impact on both the natural history and the malignant transformation. As a 
consequence, radical surgery becomes the goal in the treatment of diffuse gliomas in order to 
prevent malignant transformation and to prolong overall survival [52]. Additionally, radical 
surgery significantly improves seizure control compared with subtotal resection [53].
General principles of surgery, as they were underlined by Hugh Duffau, are generally 
accepted by the neurosurgical community: early radical surgery, awake surgery in high elo-
quent areas, cortical mapping, “resection according to cortico-subcortical functional and not 
oncological boundaries,” and “multistage resection in critical regions” [51]. The most difficult 
part of the operation is at the boundaries of the tumor, where even with adjuvant intraopera-
tive MRI, the distinction between normal brain and infiltrative brain is very difficult. Surgical 
experience contributes to better surgical results, but even in very experienced hands, there are 
cases in which a residual tumor could be identified on postoperative MRI (Figure 4).
Neuronavigation and intraoperative ultrasound are more and more used in order to improve 
the surgical resection, since they are able to reveal large residual tumors. Enhanced intraop-
erative ultrasound is at the beginning of experience, more studies being necessary to establish 
its usefulness in diffuse astrocytomas resection (Figure 5) [54].
2.1.1.2. Adjuvant therapy
Factors to take into consideration for immediate postoperative therapy are those considered 
risk factors for worse outcome namely age > 40 years, preoperative tumor diameter > 4 cm, 
incomplete resection, astrocytic histology, and absence of 1p/19q codeletion [55]. In this per-
spective, cases with DA IDH-mut completely resected, in young patients (<40 year), are candi-
dates for close clinical imagistic observation and no adjuvant therapy is recommended in the 
immediate postoperative period. However, it is expected that these tumors will recur, so addi-
tional surgical and adjuvant therapy will be added at the time of progression. For tumors with 
subtotal removal, in patients older than 40 years of age, immediate postoperative treatment is 
recommended. Concerning adjuvant radiotherapy, the recommendation is in favor of lower 
doses (45–50.4 Gy) which are equivalent in terms of results with the high doses (59.4–64.8 Gy) 
but with reduced toxicity. Relative to chemotherapeutic regimen, actual data suggest that the 
PCV (procarbazine, CCNU, and vincristine) formula is superior to temozolomide regimen in 
terms of overall survival for the treatment of DA IDH-mut, mostly in cases with codeletion of 
1p/19q genes [19].
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2.2. Diffuse astrocytoma IDH wild type
Definition. This astrocytoma is a diffuse growth pattern astrocytoma without the IDH muta-
tion. WHO 2026 lists it as a rare and provisional entity. Most tumors falling under this defini-
tion can be classified with the help of genetic testing as a variety of other entities with different 
clinical evolutions.
Clinically, their behavior is not different from the DA IDH-mut.
The standard MRI findings are generally the same, the presence of a more intense enhance-
ment suggesting an increased microvascularization and, as a consequence, a more aggressive 
evolution. As it was already mentioned, the presence of 2HG peak on MR spectroscopy is 
suggestive for IDH1 mutation, so the absence of this peak could serve as an indicator for a 
wild-type tumor. 2HG was also studied as a marker for the response to adjuvant therapy [56].
Figure 4. Preoperative FLAIR MR sequence (a) and immediate postoperative axial CT (b) and 3 months postoperative 
FLAIR examination revealing a complete removal of an insular grade II DA. (c)  One year follow-up axial FLAIR MR 
examination reveal complete removal of tumor with no local signs of recurrence.
Figure 5. Preoperative coronal FLAIR (a), axial T2W (b) and intraoperative ultrasound examination (c) before resection 
of a diffuse astrocytoma subtotally removed as it is demonstrated by intraoperative ultrasound (f) and immediate 
postoperative CT scan (d and e).
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2.2.1. Multimodal treatment
2.2.1.1. Surgical treatment
Surgical treatment with the goal of early radical surgery is nowadays the first step in the 
standard of care of low-grade gliomas. Complete tumor removal based on functional borders 
more than on imagistic ones with the help of neuronavigation, awake surgery, and intraoper-
ative neurophysiological monitoring (IEM) proved to offer a longer progression-free survival 
(PFS) and overall survival (OS) compared with subtotal removal, with reduced neurological 
deficits [57, 58].
2.2.1.2. Adjuvant treatment
Knowing that the wild-type astrocytomas have a worse prognosis, a low-dose radiotherapy 
regimen in the immediate postoperative period is recommended instead of close clinical imag-
istic observation. There are arguments in favor of radiotherapy in terms of prolonged PFS but 
not necessarily the OS [59]. Due to the fact that the patients receiving associated radiotherapy 
and chemotherapy have an improved long-term survival [60], a combined radio-chemother-
apy regimen seems to be recommendable. Further studies will have to determine whether 
temozolomide, which was historically preferred by neuro-oncologists due to its lower toxicity 
and oral administration, is superior or not to PCV [61].
2.3. Diffuse astrocytoma NOS
Definition. A diffuse astrocytoma for which the presence of the IDH mutation could not be 
determined.
2.4. Oligodendroglioma, IDH-mutant, and 1p/19q codeleted
Definition. Tumor with a diffuse growth pattern, slow growth, showing IDH mutations and 
the 1p/19q codeletion. Oligodendrogliomas develop many similarities with DA IDH-mut con-
cerning clinical presentation, imagistic diagnosis, and therapeutical management.
Grading. Grade II WHO.
Clinical presentation. The classical presentation of a patient with oligodendroglioma 
is with seizures that precede with years and with other neurological signs like mental 
disturbances, neurological deficits, or signs of increased intracranial pressure (mostly 
headache). Even in patients with no seizures at the onset, they will develop such clinical 
manifestations during the course of disease. The brutal debut due to an intratumoral hem-
orrhage although rare, is more frequent in oligodendrogliomas than in other low-grade 
gliomas [62].
Imaging. CT scan is usually the first imagistic tool in emergency, and for more than 50% of oli-
godendrogliomas that present intratumoral calcification, it is a useful diagnostic method. On 
CT scan, oligodendrogliomas are present as well-delineated cortical-based hypodense lesion 
with intratumoral or peripheral calcification. Cystic component are not rare and hemorrhagic 
regions may also be encountered (Figure 6). Contrast enhancement is absent or marginal. 
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Recently, it was suggested that presence of calcification is highly associated with 1p/19q code-
letion and, as a consequence, has a prognosis role [63].
Standard MRI reveals an hyperintense inhomogeneous lesion on T2W and FLAIR sequences, 
respectively, an inhomogeneous hypointense cortical-based well-delineated lesion on T1W 
sequences with no or discrete enhancement. Calcifications, cysts, and hemorrhagic lesions 
increase the heterogeneity of the lesion (Figure 7).
Advanced MRI techniques. As for the diffuse astrocytomas, MRI spectroscopy reveals higher 
NAA (N-acetylaspartate) peak near 2 ppm. The mIns (myoinositol) peak is relatively higher 
when compared with normal brain; the reduction of peak signaling is a possible malignant 
transformation of tumor. The NAA/Cr (creatinine) ratio is higher in low-grade gliomas, 
meanwhile the ratio Cho(Choline)/Cr is higher in high-grade gliomas [64]. As it was already 
mentioned, 2HG peaks serve as an indicator for IMD 1 mutation. Perfusion MRI, an another 
physiologic imaging sequence, reveals that relative cerebral blood volume (rCBV) is reduced 
in low-grade gliomas (LGG) compared with high-grade ones. Increase in rCBV in a LGG 
is an indicator for rapid progression and possible malignant transformation (Figure 8) [65]. 
Diffusion tensor imaging (DTI) could also add some supplementary information in order to 
differentiate LGG from high-grade gliomas (HGG) [66].
Figure 6. Axial and coronal CT scan examination of a case with an hypodense left frontal lobe lesion with intratumoral 
calcifications and discrete enhancement (a and b).
Figure 7. Axial T2W (a), axial (b) and coronal (c) FLAIR sequences of a left frontal oligodendroglioma.
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Macroscopy. It is a well-defined lesion at the interface between the white and the gray matter 
(with an affinity for the cerebral cortex). In cross-section, the surface is soft and frequent calcifica-
tions gives it a gritty look. Hemorrhagic and cystic degeneration areas can be seen.
Histological diagnosis. The aspect is that of an infiltrative tumor consisting of monomorphic 
cells. Cellularity is moderately increased, but it can vary considerably. The well-differentiated 
tumors can feature well-circumscribed nodules of increased cellularity. The nuclei are slightly 
enlarged, uniform, round (low atypia), and slightly hyperchromatic (“salt and pepper”). In 
hematoxylin-eosin, they are surrounded by a water clear cytoplasm with sharp borders, 
which gives them the artefactual aspect of fried egg or honeycomb. Typically, they show a 
network of branching capillaries in a chicken wire shape. Calcifications, cysts, and areas of 
mucoid degeneration can also be encountered. Mitoses are rare [67]. Immunohistochemically, 
the cells are IDH+ and ATRX+, and p53− [3]. GFAP and vimentin are variably expressed. 
Olig1 and Sox10 are positive but non-specific [68]. The differential diagnosis can be done with 
macrophage-rich lesions, diffuse astrocytoma, and clear cell ependymoma.
Genetic diagnosis. By definition, these tumors feature mutations in the IDH1 and IDH2 genes, as 
well as the deletion of the whole arm of the 1p and 19q chromosomes [69]. The incomplete/partial 
codeletion is present in glioblastomas and anaplastic astrocytomas. TERT mutation is associated 
with the IDH mutation and codeletion in the early onset of the tumor. CIC and FUB occur at a 
later stage [70]. The TP53 mutation is absent. As to the epigenetics, just like in the other cases, the 
IDH mutation induces a hypermethylated status—G-CIMP [38]. The methylation of the MGMT 
promoter is associated with a better survival rate, given the response to treatment (Figure 9) [71].
2.4.1. Multimodal treatment
2.4.1.1. Surgical treatment
Surgical principles are the same with those of DA IDH-mut, gross total resection (>90% vol-
ume reduction on 24–48 h postoperative MRI) being correlated with a longer PFS and OS, 
compared with subtotal resection [57].
Figure 8. T1W + C sequence (a), DTI (b) and perfusion MR (c) sequences in a patient with a LGG with a nodule of contrast 
enhancement corresponding to a region of increased rCBV; the patient presented 4 years previously for epileptic fits; 
MRI examination performed at that time was suggestive for a LGG, but the patient refused any treatment except the 
antiepileptic one; readmitted for signs of increased intracranial pressure and clear imagistic findings for progression and 
malignant transformation.
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The use of neuronavigation with co-registered preoperative T2W and FLAIR sequences and 
CT scan data in the presence of intratumoral calcification improved the grade of resection 
(Figure 10). As for other LGG, intraoperative electrostimulation mapping (IEM) on awake 
patient greatly improved not only functional outcome of the patient but also made possible to 
extend safely the grade of resection, with a great impact on the prolonged survival rate [72].
Figure 9. Molecular sand histopathological diagnosis of oligodendrogliomas.
Figure 10. Preoperative T2W and T1W + C (a and b), respectively; 12 months postoperative T2W and T1W + C (c and 
d) sequences of a case with left frontal oligodendroglioma completely removed without any neurological deficit; (e) 
intraoperative aspect after completion of radical removal of a right temporal low-grade glioma with the preservation of 
Labbe vein (personal archive).
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Despite the fact that there are no randomized trials comparing grade of resection with and 
without intraoperative MRI, it is intuitive that having real-time data on the progression of 
removal is at least useful for completion of tumor excision. An alternative is the intraoperative 
ultrasound which can detect significant remnants in real time without interruption of surgery 
(Figure 11). The introduction of new equipment with 4D and contrast enhancement dramati-
cally improves the quality of images, but their role in detecting fine details in low-grade glio-
mas is to be established in near future.
2.4.1.2. Adjuvant treatment
Immediate postoperative radiotherapy of completely removed oligodendroglioma IDH-mut 
1p/19q codel is still under debate. Based on the results of EORTC 22845 trial which revealed 
that there is no significant difference in terms of OS between patients receiving immediate 
Figure 11. Staged resection of a high-grade gliomas with the aid of intraoperative contrasted ultrasound: after the dural 
opening (a), partial resection (b) and after complete resection (c) of the tumor.
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postoperative radiotherapy and those receiving radiotherapy as a salvage therapy, the actual 
recommendation is to delay radiotherapy until signs of progression are evident. In cases of 
incompletely removed tumors or in the presence of any imagistic or clinical signs of progression, 
combined radiotherapy and PCV chemotherapy is superior to radiotherapy alone (Figure 12) [73].
Some authors argued that even in cases with foci of anaplasia imbedded in low-grade glioma, 
the total resection is sufficient for a long-term PFS, and no adjuvant treatment is needed; but 
this is not the standard of care as the authors already mentioned at the conclusions [74].
2.5. Oligodendroglioma, NOS
Definition. Infiltrative tumor with the histopathological aspect of oligodendroglioma, for 
which the genetic determinations relevant for the diagnosis (IDH mutation and 1p/19q code-
letion) cannot be determined.
3. High-grade gliomas
3.1. Anaplastic astrocytoma, IDH-mutant
Definition. Tumoral proliferation which, from a histopathological point of view, displays an 
astrocytic phenotype, a diffuse growth pattern and proliferative activity, and which, geneti-
cally speaking, features mutations in the IDH1 or IDH2 genes.
Figure 12. Serial follow-up MRI examination of a patient with oligodendroglioma completely removed in September 
2009, presenting with imagistic signs of progression 1 year later, but without any additional clinical manifestation; 15 
months later the patient was readmitted for signs of increased intracranial pressure and clear findings of malignant 
transformation; re-operated in emergency, patient followed the standard radio-chemotherapy regimen.
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Grading. Diffuse astrocytoma is deemed grade III WHO.
Clinically, the patients experience seizures, headache, neurocognitive disturbances, and neu-
rological deficits in more advanced stages.
Imaging. MRI features are quite variable, with isointense mixed with hypointense signaling 
on T2 W sequences and heterogeneous hyperintensity in T2W and FLAIR sequences. The 
contrast enhancement is subtle or is lacking in majority of cases [75] (Figures 13 and 14).
Macroscopy. Anaplastic astrocytoma appears as an expansion of the tissue tending to infil-
trate the surrounding nervous structures, but without destroying them. It is difficult to distin-
guish from the grade II astrocytoma, but the increased cellularity makes it easier to identify 
the edges of the tumor. Also, in cross section, we see areas of low consistency, granular, or 
opaque. Cysts are rarely encountered.
Histological diagnosis. The aspect is that of a tumoral proliferation with astrocytic phenotype 
and a diffuse growth pattern. As compared to grade II astrocytomas, it shows increased cellular-
ity, anaplasia, and mitotic activity. These three parameters can vary between grade II astrocy-
toma and glioblastoma and must therefore be assessed in context. A heightened mitotic activity 
is sufficient for a diagnosis, even if the cellularity is low or normal. Also, just one mitosis in a ste-
reotactic biopsy can be sufficient for a diagnosis. There are also atypical mitoses. In a large biopsy, 
Figure 13. Upper row: left frontal lesion hyperintense in T2W (a) and FLAIR (b) sequences with no contrast and T1W 
sequence (c) MRI in a 24 years old men diagnosed with grade III astrocytoma; lower row: left frontal lesion having 
similar characteristics in T2W (d) and FLAIR (e) sequences but with a discrete enhancement in T1W (f) sequences 
revealed in the young men’s father MRI examinations, operated 5 years before with an anaplastic astrocytoma (personal 
archive) suggesting a hereditary determinism in this particular case.
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the presence of several mitoses is not sufficient for a diagnosis. The nuclei are larger, hyperchro-
matic, and their shapes vary more than in the case of grade II astrocytomas, while the nucleoli are 
more visible. Multinucleated cells, gemistocytes, small cells, and perivascular lymphocytes can 
also be seen. There are no calcifications, necrosis, or microvascular proliferation [76].
The immunohistochemical profile is the same as in the grade II IDH-mutant diffuse astrocytoma: 
Olig2+, IDH1 R132H+, ATRX−, and p53+ in some cases. The Ki-67 proliferation index is gener-
ally high (5–10%), but it can vary considerably [77]. The differential diagnosis is performed 
with reactive gliosis, demyelinating diseases, progressive multifocal leukoencephalopathy, 
grade II astrocytoma, glioblastoma, and anaplastic oligodendroglioma.
Genetic diagnosis. Generally, it matches that of grade II astrocytomas. The IDH 1/2 mutation 
is present by default, in association with TP53 and ATRX. Chromosome arm 9p and 19q losses 
are more frequent in grade III tumors. As with grade II astrocytomas, the presence of the IDH 
mutation means a better prognosis, with the median survival rate for these patients being 
9.3 years. The presence of EGFR, 10q loss, and 7q gain means a less favorable prognosis, and 
may suggest a molecular diagnosis of glioblastoma, even if there is no indication of it in the 
histology (Figure 14) [35]. By definition, the 1p/19q codeletion is absent.
3.2. Anaplastic astrocytoma, IDH wild-type
Definition. Tumoral proliferation which, from a histopathological point of view, displays an 
astrocytic phenotype with a diffuse growth pattern, proliferative activity, and increased ana-
plasia, and which, genetically speaking, does not feature mutations in the IDH gene.
Grading. Grade III tumor.
Genetic diagnosis. One in five anaplastic astrocytomas does not feature the IDH mutation, the 
genetic profile and the clinical evolution of these tumors being that of wild-type glioblastoma.
Figure 14. The immunohistochemical analysis (Clone H09) of the IDH1 R132H mutation performed on a patient with 
anaplastic astrocytoma. Infiltrating tumor cells positives at cytoplasmic level are observed in a background of negative 
normal astrocytes (left). In vivo single-voxel localized PRESS spectra were performed for the same patient. Black line 
represents the sum of spectra obtained during MRS. Pink line represent the spectra of 2-hydroxyglutarate identified at 
TE 35 ms (right).
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3.3. Anaplastic astrocytoma NOS
Definition. Diffuse anaplastic astrocytoma for which the presence of the mutation in the IDH 
gene could not be determined.
Grading. Grade III tumor.
3.3.1. Multimodal treatment
3.3.1.1. Surgical treatment
Being malignant tumors, early radical surgery represents the first step of the multimodal treat-
ment of anaplastic astrocytomas. Due to the diffuse infiltration of the brain, radical excision is 
rarely achieved, meaning that if 1% of the initial volume remains in place, a local recurrence 
is almost certain. Additionally, the location of tumor in high eloquent areas prevents a radical 
excision in order not to produce severe neurological deficits. The main goals of surgery in high-
grade gliomas (HGG) are to reduce the mass effect, to obtain relevant pathological tissue, to 
reduce the tumor burden, and to prolong survival with improved quality of life. There are many 
factors influencing OS in high-grade gliomas such as preoperative Karnofsky score, age, general 
and neurological status at the preoperative and postoperative period, pathology and genetics of 
the tumor, grade of resection, response and tolerance to the adjuvant therapy. Among all these 
factors only those related to surgery could be influenced, namely the grade of resection and the 
neurological status after the operation [78]. There is a very delicate balance between the radical 
surgery and preservation of neurological function. The more aggressive the surgery, the higher 
the risk for neurological deficiencies stands (Figure 15). After the publication of the trial con-
ducted by Stupp and in 2005 [79], in which the role of surgery was minimized, a large amount 
of studies were published underlying the importance of gross total resection (GTR) compared 
not only with biopsy but also with near total resection (NTR) and subtotal resection (STS) as a 
factor that independently influences OS in HGG. For example, in anaplastic astrocytomas, there 
is a difference of 12 months in median of survival in favor of GTR compared with STR [80].
A retrospective study performed by us on 266 cases of HGG reveals the fact that gross total 
removal (GTR) greatly influences survival compared with STR. At the three periods of moni-
toring (12, 18, and 24 months), the difference regarding survival mean between GTR vs. STR 
ranged from 2.8 months (at 12 months monitoring) to 4.4 months (at 18 months monitoring) 
up to 5.1 months (at 24 months monitoring) including all types of malignant gliomas. We also 
found that the type of surgery and the age are prognostic factors that significantly influenced 
in all three periods of monitoring, while the histopathology was a prognostic factor for sur-
vival only at the 24 months monitoring (Table 1) [81].
A more detailed discussion regarding the role of surgery will be presented later in the chap-
ter, along with the types of glioblastomas.
3.4. Anaplastic oligodendroglioma, IDH-mutant, 1p/19q-codeleted
Definition. Infiltrative tumor with the histopathological aspect of oligodendroglioma show-
ing a significant proliferative activity and microvascular proliferations.
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Grading. The tumor is grade III WHO.
Clinically, the most frequent presenting symptom is seizures, less frequent than in the lower-
grade tumors, accompanied with signs of increased intracranial pressure and cognitive defi-
cits. Other signs are related to the location of tumor [82].
Imaging. On MRI studies, they are typically heterogeneous, predominantly hypointense in 
T1W, and respectively hyperintense in T2W sequences. The frontal lobe cortical based location, 
the presence of calcification, cystic degeneration and hemorrhage, and intense enhancement 
along with minimal perilesional edema are more suggestive for anaplastic oligodendrogli-
oma than for other gliomas. For follow-up imagistic studies, the T2W and FLAIR sequences 
are more sensitive in identification the local progression [83]. CT scans usually performed in 
emergency may clearly define calcification and hemorrhagic changes (Figure 16).
Macroscopy. As compared to grade II oligodendroglial tumors, they show additional necrotic 
areas.
Microscopic diagnosis. Increased cellularity, in a pattern that is infiltrative or compact with 
little intervening parenchyma. The cells have the characteristic fried egg aspect, but a signifi-
cant pleomorphism or giant multinucleated cells can also occur. Significant mitotic activity is 
Figure 15. Integrated histological and molecular diagnosis of anaplastic astrocytoma IDH-mutant.
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also present [84]. Sarcomatoid areas can be seen. The minigemistocytes are more numerous 
than in the case of grade II oligodendrogliomas [85]. As a characteristic, the chicken wire 
aspect is accompanied by microvascular proliferation. As opposed to grade II oligodendro-
gliomas, they can involve palisading necrosis. Secondary structures can also be encountered. 
Immunohistochemically, the profile is that of grade II tumors, with a higher proliferation 
index evinced by way of Ki-67 (generally >5%). The differential diagnosis can be done using 
clear cell ependymoma, glioblastoma, and anaplastic astrocytoma.
Figure 16. Preoperative T2W and T1W+ C (a and b) sequences of a case with left frontal anaplastic astrocytoma completely 
removed; follow-up MRI performed at 4 months postoperatively and after concomitant radio- and chemotherapy with 
temozolomide showed no signs of local recurrence (c and d).
Disease free 
interval
Log rank (Mantel-
Cox) factor: age 
(<65 years/≥65 years)
Log rank (Mantel-Cox) 
factor: type of surgery 
(gross total removal/
subtotal removal)
Log rank (Mantel-
Cox) factor: 
histopathological 
diagnosis
Log rank 
(Mantel-Cox) 
factor: gender
12 months 0.000 0.000 0.090 0.296
18 months 0.000 0.000 0.122 0.836
24 months 0.000 0.000 0.031 0.756
Table 1. Disease free interval regarding the age, type of surgery, and histopathology.
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Genetic diagnosis. Apart from the IDH mutation and the codeletion of the whole arm of the 
1p and 19q chromosomes, the concurrent polysomy of 1p and 19q is more frequently encoun-
tered in anaplastic oligodendrogliomas [86]. Other chromosomal aberrations can occur: gain 
of 7, 8q, and 15q, and losses of 4q, 18, and 22q. Just like in the case of low-grade tumors, TERT, 
CIC, and FUBP1 mutations are present. Epigenetically, the IDH mutation induces G-CIMP, 
while in most cases MGMT is hypermethylated [87].
3.5. Anaplastic oligodendroglioma, NOS
Definition. The diagnosis concerns the anaplastic oligodendrogliomas whose genetic profile 
(IDH mutation and 1p/19q codeletion) cannot be determined.
The diagnosis of oligoastrocytoma has been discontinued following the latest WHO classification.
3.5.1. Multimodal treatment
As for the other types of gliomas, the grade of surgical resection is an independent factor for 
PFS and OS. As a consequence, GTR is recommendable wherever is possible without neuro-
logical damage (Figure 17).
Figure 17. Axial (a) and coronal (b) contrasted CT scan demonstrating the presence of a voluminous expansive lesion 
with large cystic components and peripheral calcification with a reduced perilesional edema, aspect highly suggestive 
for an anaplastic oligodendroglioma; after GTR the axial T2W (c) and coronal FLAIR (d) sequences at 2 years follow-up 
do not indicate a local progression.
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Due to the good response of anaplastic oligodendrogliomas to chemotherapy, the subtotal 
resection with preservation of neurological function is also an acceptable surgical strategy [88].
3.5.1.1. Adjuvant treatment
Adjuvant treatment is recommended in anaplastic oligodendrogliomas on a regular basis. 
Recent studies failed to demonstrate a benefit of temozolomide over the classical PCV reg-
imen, which remains the main tool for first-line chemotherapy in anaplastic oligodendro-
gliomas. Radiotherapy is reserved for cases of clear imagistic evidence of tumor progress. 
Fractions of 1.8–2 Gy for a total dose of 54–60 Gy are the actual recommended radiotherapy 
regimen based on clinical evidence [89].
3.6. Glioblastoma IDH wild-type
Definition. High-grade tumor with a diffuse growth pattern and a dominantly astrocytic 
differentiation showing cellular pleomorphism, nuclear atypia, and brisk mitotic activity. 
Glioblastomas are characterized by the presence of necrosis and microvascular proliferations.
Grading. Glioblastomas are grade IV WHO.
Clinically, the evolution is usually short due to the high growth rate of the tumor [90]. Almost 
40% of the patients are admitted for surgical treatment in the first month from the clinical 
debut marked by progressive headache (almost 80% of cases). Mental disturbances, changes 
in personality, and neurological deficits are subsequent manifestations of the evolution of 
the disease. Seizures are less common (18.9% in our study on 276 cases) then in the LGG [81].
Imaging. Native CT scan is usually performed in emergency and reveals a heterogeneous 
expansive process with significant mass effect. Addition of contrast enhancement clearly 
defines a variable-enhanced lesion with perilesional edema, the classical aspect of a ring 
enhancement circumscribing an necrotic area which is frequently present (Figure 18).
Once the suspicion brain tumor is raised, an MRI examination will more accurately define the lesion. 
T1W and T2W sequences are able to reveal the tumor and also other pathological changes within 
or around it: edema, necrosis, hemorrhage, and calcifications. In addition, the FLAIR sequences 
will demonstrate a hyperintense perilesional halo, which is in fact a combination of tumoral infil-
tration and edema. On enhanced T1W sequences, the classical appearance of “ring enhancement” 
delineating a central necrosis is the most eloquent aspect of glioblastoma (Figure 19).
Nevertheless, Advanced MRI techniques will offer functional elements in favor of a malignant 
lesion. On MR spectroscopy, glioblastoma presents higher Cho (Choline) peaks along with a 
higher Cho/Cr (creatine) ratio. This ratio is additionally elevated owing to the decrease of Cr 
compared with the normal level. Lactate and lipid peaks that indicate necrosis and disruption 
of myelin sheaths could also be detected in glioblastomas [91]. On DWI, high-grade gliomas 
typically present a restricted diffusion. DTI studies may help in differentiating HGG from 
LGG trough fractional anisotropy (FA), which is higher in the former [92]. On tractography, 
HGG will show a disruption of tracts. MRI perfusion studies reveal a heterogeneous relative 
cerebral volume (rCBV), demonstrating areas of increased cellularity and mitotic activity in 
glioblastomas (Figure 20) [93].
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Advanced MRI techniques are also useful for differentiating between local recurrence and 
radionecrosis (pseudoprogression). Recently, it was showed that rCBV as a single examina-
tion modality is superior to volume transfer constant (Ktrans) or apparent diffusion coef-
ficient (ADC) for the prediction of local recurrence. The combination of rCBV and Ktrans 
improves the accuracy of the recurrence diagnosis [94].
Macroscopy. Poorly delineated lesions, with yellow, white, or granular areas caused by the 
necrosis, surrounded by grayish tumoral areas. In glioblastomas, cysts filled with a turbid 
liquid are formed through the liquefaction of the necrotic tissue. Typically, in cross section, 
we see purple-red or brown-red areas caused by the hemorrhage occurred during the pro-
gression of the tumor. The hemorrhages can be massive. Also in cross section, we can see 
thrombotic vessels with the aspect of “dark veins.”
Microscopic diagnosis. The histology of the tumor is extremely variable and the cellular com-
position is highly heterogeneous. The astrocytic nature of the tumor can be identified in the 
well-differentiated tumors. In the poorly-differentiated ones, the astrocytic phenotype is rec-
ognized with considerable difficulty [95].
There are a number of cellular morphologies common to glioblastomas: fibrillary astrocytes, 
gemistocytes, smalls cells (highly infiltrative, bipolar, and mitotically active), epithelioid, 
Figure 18. Axial T2W (a), axial FLAIR (b) and coronal T1W + C (c) sequences of an extremely rare intraventricular 
anaplastic oligodendroglioma completely removed, as it is demonstrated by the 6 months follow-up MRI (d–f).
Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management
http://dx.doi.org/10.5772/intechopen.76205
117
Figure 19. Coronal (a) and axial (b) preoperative contrasted CT scan examination of a case with left temporal 
inhomogeneous expansive lesion with a “ring enhancement” highly suggestive for a glioblastoma; (c) and (d) immediate 
postoperative contrasted CT scan examination demonstrating gross total removal of the tumor.
Figure 20. T2W (a), FLAIR (b) and T1W + C MRI (c) sequences of a left frontal expansive lesion, aspects that are highly 
suggestive for a glioblastoma.
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rhabdoid, granular, or lipidized cells. The areas that contain astrocytes whose phenotype is 
more easily identified can be more or less clearly separated from the areas of high pleomor-
phism. The cells are poorly differentiated, with pleomorphism, significant atypia, and brisk 
mitotic activity. The presence of a cellular population having a different phenotype indicates 
the emergence of a new tumoral clone through new genetic events [96].
The dominance of a specific cell type in the tumor generates a pattern that is useful in the 
diagnosis of small cells, with a neuroectodermal component, with an oligodendroglial com-
ponent, with granular cells, with gemistocytes, and with lipidized cells. This is an indicative 
for the diagnosis but insufficient for a distinct variant.
The small cell glioblastoma pattern consists of small, round, or slightly oblong monomorphic 
cells, faint atypia, and hyperchomatic nuclei surrounded by a small amount of cytoplasm. 
One characteristic is the heightened proliferative activity. The GFAP is variably expressed, 
and when present, it can be seen at the level of delicate processes. Several morphological 
elements found in this pattern, such as the monomorphic nuclei surrounded by a clear halo, 
chicken wire vasculature, or calcifications, can cause problems in the sense of a differential 
diagnosis with oligodendrogliomas [97]. The difference is made here by molecular tests, 
which evidence a molecular profile typical for glioblastomas: EGFR amplifications, Ch 10 
losses, IDH wild-type, no 1p/19q codeletion [98].
The primitive neuronal component glioblastoma is a glioblastoma featuring nodules that show 
neuronal differentiation. These nodules are clearly distinguishable from the rest of the tumor. 
Cellularity is increased, and so is the proliferation index in these areas. The cells are similar to 
those in other CNS embryonal neoplasms or they form Homer-Wright rosettes. The immuno-
histochemical profile is closer to that of neuronal precursors, being positive for Synaptophysin 
and with a low GFAP expression [99].
The glioblastoma with an oligodendroglioma component contains foci (often minor) of classic oli-
godendroglioma, associated with necrosis. The presence of the two components in the same 
tumor, in association with necrosis, raises the possibility of a grade IV oligoastrocytoma. While 
the presence and the size of the necrosis means a less favorable prognosis, this type of tumor, 
nevertheless, has a better prognosis than the standard glioblastomas [100]. From a molecular 
point of view, this histopathological aspect includes several molecular groups, lacking a distinct 
molecular signature. The tumor may or may not feature IDH1 mutations or 1p/19q codeletion, 
and also TP53 mutations, Chr 7 gain, Chr 10 loss, EGFR, and PDGFRA amplifications [101].
Granular cells glioblastomas are tumors with a distinct histological aspect, characterized by an 
aggressive behavior, despite a morphological character indicative of a grade II or III tumor. 
The cells are large, similar to macrophages. They are positive for CD163 and CD68 due to the 
high lysosome content. They are generally negative for GFAP, even if a certain positivity can 
be occasionally seen in the peripheral cellular areas. They are little understood from a molec-
ular point of view, but a study involving array-based comparative genomic hybridization 
has indicated a genetic profile very similar to the conventional glioblastomas (gain of CHr 7, 
loss of Chr. 1p, 8p, 9p, 10p, 13q, and 22q, EGFR amplification, and homozygous deletion of 
CDKN2A). There are no IDH mutations and no 1p/19q codeletion [102].
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The lipidized glioblastoma occurs rarely, a significant number of large cells with a lipidized 
(foamy) aspect being present against a histological background typical for a standard glio-
blastoma. In such cases, the diagnosis of pleomorphic xanthoastrocytoma cannot be ruled 
out. From a genetic point of view, they are little studied [103]. Phenotypically, they are similar 
to adipocytes, but the fact that they are positive for GFAP comes to confirm their glial origin.
Three histological variants are known: giant cell glioblastoma, gliosarcoma, and epithelioid 
glioblastoma.
Giant cell glioblastomas are characterized by the occurrence of giant multinucleated cells (up 
to 20 nuclei), with prominent nucleoli. Also noticeable are the small syncytial fusiform cells. 
The infiltration patterns typical for the diffuse gliomas are less visible in this variant. It fea-
tures a significant component of connective tissue in the shape of a reticulin network [104]. 
Atypical mitoses are frequent. Another characteristic feature of this variant is the perivascular 
positioning of tumor cells (pseudorosette-like pattern). There is a significant ischemic necro-
sis. Microvascular proliferation and the pseudopalisading necrosis are rarely encountered. 
Perivascular lymphocytes may be present [105]. The neuronal immunohistochemical markers 
are negative. GFAP has variable expression. The nuclear expression of p53 shows a high inci-
dence of TP53 gene mutation [106]. The presence of the connective component, together with 
their circumscribed nature, makes it more difficult to distinguish macroscopically between 
these tumors and meningiomas and metastases.
From a molecular point of view, they showed a high incidence of PTEN and TP53 mutations; 
but, no EGFR amplifications and no homozygous deletion of CDK2A were shown. As a vari-
ant of the wild-type glioblastoma, it features no IDH mutations. The prognosis is slightly 
better than in the case of usual glioblastomas [107].
The epithelioid glioblastoma is characterized by the presence of a significant population of 
cells with an epithelioid aspect, eosinophilic cytoplasm, peripheral nucleus, and sharp bor-
der. Rhabdoid cells with discrete borders and eccentric oval nuclei can be present, as well 
as necrosis and vascular proliferations. Immunohistochemically, the GFAP has a variable 
expression [108]. The epithelial markers (EMA and CK AE1/AE5), as well as S100 and vimen-
tin, are positive. The antibody that indicates the BRAF V600 mutation is positive in 50% of 
cases [109]. From a molecular point of view, the epithelioid glioblastoma occasionally shows 
genetic events characteristic of glioblastomas (EGFR amplifications, CKD2A deletion, and 
PTEN mutation). As a variant of the wild-type glioblastoma, it features no IDH mutations. 
The prognosis is worse than in the case of other glioblastomas [110].
Gliosarcoma is characterized by a monoclonal proliferation with a highly malignant biphasic 
histological pattern, astrocytic and mesenchymal. The astrocytic component displays the typi-
cal aspect of a glioblastoma. The mesenchymal component consists of long bundles of spindle 
cells, closely packed, showing malignancy (atypia, necrosis, and mitosis), similar to fibro-
sarcoma or the malignant fibrous histiocytoma [111]. The confirmation of malignancy in the 
mesenchymal component is required in order to differentiate it from desmoplasia, which can 
occur in the glioblastomas with meningeal invasion. Elements of differentiation can appear 
(cartilage, bone, muscle, and osteoclastic giant cells) [112]. The presence of connective tissue 
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structures in the mesenchymal component (but not in the astrocytic one) can be demonstrated 
using staining for reticulin and trichrome. As with the giant cell glioblastomas, the mesenchy-
mal component makes the tumor macroscopically similar to a metastasis or meningioma. This 
entity can also appear in ependymomas and oligodendrogliomas, de novo or following treat-
ment [111]. Immunohistochemically, the astrocytic component is positive for GFAP, while 
the sarcomatoid one is negative. P53 is positive in both components. IDHR132H is negative. 
Genetically, this variant shows PTEN and TP53 mutations, as well as CDK2A deletions. There 
are no EGFR amplifications [113]. The epithelial-mesenchymal transition in the sarcomatoid 
component is highlighted by the SNAIL and TWIST expression.
Necrosis and microvascular proliferations are required for a diagnosis.
The microvascular proliferations are in direct relation with the necrosis, hypoxia being a sig-
nificant factor that stimulates the formation of vessels by way of HIF1A and VEGFA [114]. 
Another characteristic is the thrombosis of small vessels. Although, in glioblastomas, vascu-
larization is very well represented, the vascular structures are immature and largely incapable 
of compensating for the hypoxia caused by the exuberant proliferation [115].
Necrosis, of the coagulative type, is typical for glioblastoma. It affects both the cells and the 
vascular structures and is indicative of the extremely high proliferation rate associated with 
this type of tumor. It is considered to be an aggressive factor in astrocytic tumors, its size 
being associated with a lower survival rate. In the necrotic areas, we can see “shadows” of 
the dilated vessels surrounded by tumor cells in various stages of decay [116]. We can also 
see vessels that still contain oxygenated blood surrounded by viable cells. Undoubtedly, the 
high proliferation rate of glioblastomas plays an important part in the onset of necrosis, as 
there is a mismatch between the need for oxygen and the number of functioning vessels. As 
in the vicinity of the necrotic areas, we notice venal occlusions and vascular thrombosis, and 
it has been hypothesized that this is the mechanism that could trigger or spread the necrosis. 
Lesions of the endothelium trigger the release of procoagulants, which generate microscopic 
or macroscopic vascular thrombosis. Vascular thrombosis is usually accompanied by the so-
called pseudopalisading [25]. This is caused by the migration of cells from the central necrotic 
area to the more oxygenated exterior ones, in a “moving away wave” toward the vessels unaf-
fected by thrombosis and capable of maintaining a level of oxygenation sufficient for their 
survival. In an attempt to somewhat restore the level of oxygenation, these cells also secrete 
proangiogenic factors (VEGFs), causing the vascular alterations mentioned above [117].
A perivascular positioning of lymphocytes can occur in the areas with gemistocytes. In glioblas-
tomas, the number of lymphocytes can vary, and they are mainly LT CD8. Quite interestingly, the 
presence of an extensive LT CD8 infiltration has been identified with the long-term survivors. LT 
CD4 and LB are also present, but in small numbers. Microglia and histiocytes can also be seen [118].
Immunohistochemically, GFAP has a positive expression, its variability reflecting the hetero-
geneous nature of the tumor. Sarcomatous and primitive cellular components are negative, 
while the gemistocytic component is strongly positive. It is also positive in the lipidized vari-
ant. S100 and Olig2 are positive in glioblastomas and are quite useful in the diagnosis of poorly 
differentiated tumors [119]. Nestin is of particular importance in the differential diagnosis in 
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regard to other high-grade gliomas, as it is positive in glioblastomas [120]. P53 is positive in the 
glioblastomas with a missense mutation of TP53 [121]. Together with WT1 (which can be posi-
tive in low-grade gliomas), it makes the distinction between tumor cells and the reactive post-
treatment cells [122]. EGFR indicates the relative amplification of the gene, being expressed in 
45–95% of cases. EGFRvIII is present in one third of all cases [123]. The expression of Ki-67 var-
ies. A positive IDH R132H is incompatible with the diagnosis of IDH wild-type glioblastomas.
Genetic diagnosis. Glioblastomas were the first tumors investigated by The Cancer Genome 
Atlas (TCGA), which highlighted alterations in the signaling pathways of EGFR, PDGFR, 
PI3K, NF1, TP53, and Rb [124]. The genetic profile of wild-type glioblastomas differs from that 
of IHD mutated glioblastomas, which are considered secondary and which have a genetic 
profile very similar to that of grade II and III astrocytomas. The characteristic genetic altera-
tion in glioblastomas is 7p gain combined with 10q loss [125].
In what concerns the tyrosine kinase receptors and their signaling pathways (PI3K/PTEN/AKT/
mTOR and EGFR/RAS/NF1/PTEN/P13K), EGFR is the amplified gene most frequently pres-
ent in primary glioblastomas, but it is more rarely encountered in the secondary ones [126]. 
The amplification is accompanied by different truncations in the same tumor. The best known 
one is EGFRvIII, present in nearly half of the glioblastomas with amplified EGFR. The struc-
ture of the receptor is similar to v-erb, and it activates independently of the ligand. Other pos-
sible amplifications accompanied by truncation are PDGFRA and MET [127].
The PTEN gene suffers changes almost exclusively in the primary glioblastomas, either by the 
way of a missense mutation in the area homologous to tensin/auxilin, or following truncation 
at various sites caused by the loss of the chomosomal region [128].
The TP53/MDM2/MDM4/p14ARF signaling pathway is affected in both primary and secondary 
glioblastomas, especially in the secondary ones, and it is also present in grade II and III astrocyto-
mas. MDM2 amplification is a mechanism whereby the proapoptotic and antiproliferative control 
of p53 is eluded and encountered in the glioblastomas that do not present TP53 mutations [129].
The CDKN2A locus generates several CDKN2 and p14ARF proteins that act as tumor sup-
pressors. The loss of p14ARF expression is encountered in glioblastomas, being correlated 
with the methylation of the promoter of the deletion of the CDKN2 gene.
The CDKN2A/CD4/RB1 signaling pathway is altered in most glioblastomas and it occurs in both 
primary and secondary glioblastomas. The mutations of the RB1 gene are rare, and the meth-
ylation of the promoter followed by the loss of protein expression is more frequent in second-
ary glioblastomas than in the primary ones [7].
TERT can show mutations at the level of the promoter, especially in wild-type glioblastomas, 
being mutually exclusive with TP53. The occurrence of the mutation (in one of the two hot 
spots) is followed by the accumulation of the GABP transcription factor at the level of the 
promoter, leading to the aberrant expression of the gene [130].
The IDH gene is not mutated by definition in wild-type glioblastomas, and the evaluation of 
the mutational status of this gene can make the distinction between primary and secondary 
glioblastomas [131].
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Epigenetics. A study conducted in cooperation with TCGA and based on the determination of 
the genomic profile has defined four subtypes of glioblastomas: pro-neural, neural, classic, and 
mesenchymal. These subtypes are characterized by a different mutational and epigenetic profile, 
reflected in the response to treatment. These results have paved the way toward the assessment of 
the epigenetic profile of glioblastomas through a determination of the whole methylation genome 
profile in the glioblastomas with artificially induced mutations (IDH H3F3A). These experiments 
have led to the identification of six different subtypes, with a different clinical evolution [132].
MicroRNA and long non-coding RNA have also been studied in glioblastomas. miR10b con-
trols the cycle of stem and tumoral cells in GBM and is associated with a poor prognosis. The 
role of the interaction between microRNA and the oncogenetic pathways known as drivers in 
GBM, such as for instance PI3K, has also been demonstrated [133].
The currently defined histological entities have different genetic expression profiles, which 
are correlated with the grade and are a better predictor of patient outcome [37].
The methylation profile of the MGMT gene promoter is predictive for the response to the 
treatment with alkylants such as temozolomide or methylants. It is variable, being higher in 
the IDH-mutant tumors, having a G-CIMP profile [134].
3.7. Glioblastoma IDH-mutant
Definition. High-grade tumor with a dominantly astrocytic differentiation and a diffuse 
growth pattern, involving the mutation of the IDH gene.
Grading. It is ranked as a grade IV tumor.
Clinically speaking, as it is mostly located in the frontal lobe, it is often accompanied by behav-
ioral and neurocognitive changes. As the growth is more sluggish than in the case of wild-
type tumors, the signs indicating an increase in intracranial pressure are also milder.
Imaging. The areas of central necrosis typically seen in wild-type GBM are usually absent 
here. They are larger in size; the cystic structures are more frequent; and they show no enhanc-
ing zones on MRI.
Macroscopy. The aspect is that of a tumor infiltrating the adjacent cerebral parenchyma. The 
purple hemorrhagic areas and the yellow-white necrotic ones are absent.
Histological diagnosis. The morphological aspect of IDH-mutant glioblastomas is very simi-
lar to that of wild-type GBM. The areas of necrosis (ischemic or palisading) are more rarely 
encountered. On the other hand, the oligodendroglioma-like component is more frequent and 
has been associated with the presence of the IDH1 mutation [135].
Immunohistochemically, GFAP is positive and shows a certain variability. The presence of genetic 
events is reflected by the positivity for IDH1 and p53, and the negativity for ATRX. The overex-
pression of EGFR is unusual, with amplification being a characteristic of the wild-type GBM [136].
Genetic diagnosis. The presence of the IDH mutation falls under the definition of the tumor, 
and its identification makes it possible to diagnose the two types of glioblastoma. It is an early 
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event in tumorigenesis and remains present during the progression toward glioblastoma. The 
most frequent mutation of the IDH1 gene (90% of all astrocytic or oligodendroglial tumors) 
is R132H, when a guanine is replaced by an adenine (CGT->CAT). Other mutations, such as 
R132C, R132S, or R132L, occur much more rarely [137].
The ATRX gene is also mutated, the same mutation being present in the grade II and III pre-
cursor astrocytic lesions. Alongside the ATRX and IDH mutation, TP53 is more frequently 
mutated in secondary glioblastomas [31]. EGFR amplifications are rare, as opposed to the 
GBM wild-type, indicating that the genetic onset and progression pathways are different.
The genetic expression of GBM IDH-mutant is relatively homogeneous, most of them falling 
under the proneural profile [126]. Epigenetically, the occurrence of the IDH mutation induces 
an extensive hypermethylation of the DNA, all IDH-mutant tumors belonging to a hyper-
methylated phenotype [138]. The prognosis for GBM IDH-mutant is better than that for GBM 
wild-type, the survival rate being 2.4 times higher (Table 2) [139].
3.8. Glioblastoma, NOS
Definition. High-grade tumor with dominantly astrocytic differentiation and diffuse growth 
pattern, in which the mutational status of the IDH gene cannot be determined. They are grade 
IV tumors.
3.8.1. Multimodal treatment
3.8.1.1. Surgical treatment
Sir Rickman Godlee was the first surgeon who reported a resection of a glioma in 1884. More 
than one century later, the results of the treatment in malignant gliomas remained unsatisfac-
tory. Improvements of surgical techniques and technology developed in this period, includ-
ing microsurgery, neuronavigation, intraoperative MRI, intraoperative neuromonitoring, and 
5-ALA merely improved the grade of resection while increasing the postoperative quality of 
life of the patient; however, they were unable to change the inexorable course of malignant 
gliomas to recurrence and death. Perhaps the most important adjuvant of surgery was the 
introduction of radiotherapy in the middle of the last century, adding a median survival of at 
least 7 months, as it was highlighted by Ley and coworkers in 1962. In their reported series of 
Astrocytoma Oligodendroglioma GBM-wt
IDH + + -
ATRX + - -
TERT - + +
p53 + - +
1p/19q - + -
Table 2. Synthesis of the mutational status in the main categories of diffuse gliomas.
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glioma, the largest at that time, the median of survival through surgery alone was 7 months, 
whereas in the group receiving additional radiotherapy the median survival rate was at 
15 months [140]. The addition of chemotherapy further improved the survival, but despite 
the large advancements in research within the last decade, the median survival rate barely 
increased by no more than 2 months, inexorably close to the data reported 20 years ago [141].
Regarding the role of surgery, there is an increasing body of literature underlining the impor-
tance of GTR comparing with STR or biopsy. A meta-analysis covering 41,117 unique patients 
in 37 retrospective studies revealed a significant improvement of OS in GTR cases compared 
with STR [142]. Another prospective study comparing grade of resection with the aid of immu-
nofluorescence (5-ALA) versus white light also demonstrated a significant median of survival 
in favor of those with GTR (16.7 months vs. 11.7 months) [143]. Currently, there is sufficient 
data favoring GTR to encourage surgeons to increase the grade of resection, while also striv-
ing not to cause additional neurological deficits (Figure 21).
New tools were introduced in the last two decades in order to facilitate GTR, simultaneously 
with the permanent improvement of the operative microscope. Contemporary neuronavigation 
Figure 21. MRI examination of a patient with left paraventricular glioblastoma: (a) T2W sequence reveals an 
inhomogeneous lesion adjacent to occipital horn of left lateral ventricle surrounded by a hyperintense region of edema; 
(b) T1W + C sequence expose classical aspect of “ring enhancement”; (c) DWI study demonstrating a restricted diffusion 
corresponding to the region of tumor; MRI perfusion reveals a heterogeneous rCBV (d) and increased cerebral blood 
flow (CBF) corresponding to the enhanced lesion (e) ; (f) Tractography shows a disruption of fibers compared to the 
contralateral side.
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equipment offers a more precise localization with real-time correction adapted to the brain 
shift. Functional and anatomical data are merged in order to facilitate surgical interven-
tion, while also avoiding damage to eloquent areas and tracts. Intraoperative tools, such as 
intraoperative MRI, are now available in many centers, allowing surgeons to achieve a more 
complete tumor removal and, as a direct consequence, prolong survival [144]. Intraoperative 
ultrasonography, having been introduced in practice two decades prior, is at present more 
accurate in defining intracerebral lesions, especially in cases of HGG, facilitating a real-time 
control of resection (Figure 22) [145].
Contrasted intraoperative ultrasound guidance apparently adds more detailed information 
concerning the grade of resection [146].
We may conclude that surgery, and radical surgery especially, remains the first and most important 
step of the multimodal treatment in prolonging the survival of patients with malignant gliomas.
3.8.1.2. Adjuvant treatment
Whole brain radiation therapy stood as the most important adjuvant to surgery up until the 
randomized trial conducted by Walker el al. in 1980. In this trial, the authors compared the effi-
cacy of radiotherapy alone to the addition of nitrosourea chemotherapy. They demonstrated a 
Figure 22. Preoperative (a and b) and postoperative (c and d) contrasted CT scan images demonstrating the GTR of a 
left gliosarcoma.
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benefit of 2–3 months in the group treated with combined radio-chemotherapy and this com-
bination has been the standard of care for almost 25 years [147]. In time, whole brain radio-
therapy was replaced by a more focal radiotherapy, in order to prevent secondary effects of 
radionecrosis. The current standard of radiotherapy is a fractionated conformational dose of 
2Gy fractions/day, 5 days/week for a period of 6 weeks. The radiotherapy regimen must be 
initiated in three to no more than 6 weeks after the surgery [148].
Concerning chemotherapy, the actual standard consists of concomitant radiotherapy and 
temozolomide (TMZ) administration, followed by six cycles of TMZ at every 28 days. This was 
established in 2005 based on the results of the trial conducted by Stupp et al. (Figure 23) [79].
The response of the patients to the TMZ regimen is highly variable, with one of the factors 
influencing the positive response being the methylation of the MGMT promoter, which is 
present in less than 50% of glioblastoma cases. It was showed that only 65–70% of new cases 
of glioblastoma respond to TMZ; although in spite of these evidences, TMZ is still the main 
agent in multimodal treatment of glioblastoma (Figure 24) [149].
A large number of researches were made in order to decrypt the intimate mechanism of appa-
rition and development of glioblastomas, as well as the response of tumor cells to different 
chemical, physical, or biological agents. Among these agents, only few met the clinical criteria 
to be introduced in practice. Gliadel (carmustine-impregnated biodegradable wafers) on local 
application proved to add a median of survival of 2.3 months compared to the standard treat-
ment, yet was accompanied by an increased incidence of local complications (infection and 
CSF fistula) [150]. We also add our research effort on glioblastoma stem cell cultures in order 
to improve the response to TMZ by addition of new drugs like arsenic trioxide or metformin 
as sensitizers [151, 152]. New ways to deliver TMZ have been proposed [153]. Antiangiogenic 
agents (Bevacizumab) was also tested on glioblastoma stem cells with controversial response 
(in some cultures, they increased angiogenesis) (Figure 25).
The clinical trials testing Bevacizumab in newly diagnosed glioblastoma failed to demon-
strate a benefit on survival [154, 155]. Immunotherapy is a highly experimental approach 
of present days, as are other therapies. A special interest was raised in the use of an electric 
field delivered by noninvasive transducers placed on a headpiece, the so-called Novocure 
Figure 23. Ultrasonography-guided resection (a) of a diffuse astrocytoma with foci of glioblastoma (arrow) demonstrated 
on T1W + C image (b).
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treatment. The addition of this new modality to the standard radio-chemotherapy regimen 
improved the PFS and OS in glioblastoma-treated patients [156].
We can conclude that despite the huge efforts and investments made in research and therapies, 
the results still disappoint. This suggests the fact that we are possibly on the correct course, 
but against the tide. The future multimodality treatment may consist of patient-tailored treat-
ments owing to the multiple individual and tumor-related factors that influence the response 
to therapy.
Figure 24. Preoperative axial (a), coronal (b) and sagittal (c) T1W + C sequences of a patient with glioblastoma completely 
removed and treated with the standard radio-chemotherapy regimen; postoperative enhanced T1W images (d–f) reveal 
the removal of the tumor with the persistence of a small contrasted nodule, which is stable at 5 years after surgery.
Figure 25. Preoperative T1W + C sequence (a) of a glioblastoma, almost completely removed as it was revealed by 
immediate postoperative CT scan (b); the patient was not responsive to the standard adjuvant treatment as it is 
demonstrated by the postoperative enhanced MRI at 4 months (c).
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3.9. Diffuse midline glioma, H3 K27 M-mutant
Definition. High-grade infiltrative astrocytic tumor, with midline location and showing the 
K27 M mutation in the H3F3A or HIST1H3B/C genes. They are grade IV tumors.
Clinically, it is usually encountered in children and more rarely in adults. The symptoms may 
be either general (usually produced by the obstructive hydrocephalus) or focal generated 
by the involvement of different cranial nerves: facial paresis, diplopia, hearing loss, dyspho-
nia, and dysphagia. The extension of the tumor in cerebellar peduncles produces ataxia. The 
involvement of long tracts determines motor weakness. Particularly in diffuse pontine gli-
oma, behavioral changes such as pathological laughter and anxiety were described before the 
onset of other more common clinical signs [157].
Imaging. On MRI, these lesions have a diffuse homogenous appearance of hypointense in 
T1W sequences and hyperintense in T2W and FLAIR ones. The contrast is discrete or absent, 
but some focal enhancement into an infiltrative hypointense mass on T1W + C sequences 
could be detected in few cases (Figure 26).
MRI spectroscopy will differentiate these tumors from other inflammatory, vascular, or infec-
tious lesions. The Cho/Cr and NAA/Cr ratios are typically increased. An elevation of these 
ratios after radiotherapy poses the significance of progression [158].
Macroscopy. The infiltrative pattern is reflected in the size and the changes in the shape of 
the nervous structures affected by the tumor. In cross section, we can see purple hemorrhagic 
areas or yellowish-white necrotic ones.
Histological diagnosis. The aspect is that of an intensely infiltrative tumor consisting of 
small-size monomorphic, astrocytic cells. While most are accompanied by necrosis, micro-
vascular proliferations, and an enhanced mitotic index, these elements are absent in a small 
number of tumors. According to the new rule introduced by the latest WHO classification, 
whereby “molecular beats histology,” even if histologically they are grade II, they shall nev-
ertheless be deemed grade IV. Immunohistochemistry. GFAP shows a heterogeneous expres-
sion in these tumors. On the other hand, they are positive for S100, OLIG2, and NCAM1. 
Mutations of ATRX and TP53 can occur, but more rarely. An antibody targeting the protein 
modified by the presence of the H3.3 K27 M mutation can be used in the diagnosis [159].
Figure 26. In vitro 3D model of glioblastoma stem cells culture demonstrating an increase angiogenesis in contact with 
TMZ and resistance to the addition of Bevacizumab compared with the control (ctrl) (personal archive).
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Genetic diagnosis. This entity is defined by the presence of the K27 M mutation in the H3F3A 
(80%), HIST1H3B (20%), and HIST1H3C genes. The genetic profile is completed by muta-
tions in the TP53 and ATRX genes, homozygous CDKN2A deletion, and MYC, CDK4/6, and 
PDGFRA amplifications [160].
3.9.1. Multimodal treatment
This type of tumor is not amenable for surgical treatment. The single debate is related to the 
role of biopsy. The actual accepted strategy is that biopsy (open or stereotactic) is indicated 
only in atypical tumors. The term of atypical is somehow unclear, but generally it is accepted 
that the unilateral extension of tumor and the presence of cystic components or focal hemor-
rhages offer a rationale for surgery.
In centers with experience in stereotactic biopsy, this could be the method of choice. Otherwise, 
open surgery is performed, guided by the most superficial part of lesion or throughout the 
so-called “safe entry zone.” In selected cases, surgical interventions can offer the opportunity 
of cytoreductive surgery, thus creating proper conditions for radiotherapy (Figure 27) [161].
Radiotherapy is the single recommendable therapy for this kind of lesions (Figure 28). A total 
dose between 54 and 60 Gy, administered in fractions of 1.8–2 Gy, is the actual recommenda-
tion of oncologists. No chemotherapy regimen was able to demonstrate a benefit in terms of 
survival. Corticosteroids are also administered during radiotherapy. After a period of symp-
tom amelioration, the tumor will inevitably progress [162].
3.10. Pediatric diffuse astrocytic tumors
Despite having a particular clinical evolution, pediatric tumors have been lumped together 
with the adult ones, according to the histopathological similarities [163]. We now know that 
their onset and progression genetic mechanisms are different. A well-defined entity that 
occurs predominantly in children is the one described above. As opposed to adult tumors, 
Figure 27. T2W (a), FLAIR (b) and DWI (c) sequences of an infiltrative tumor into the brainstem and left cerebellar 
peduncles.
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the pediatric ones show changes in the genes regulating chromatin structure and the genetic 
expression profile. Apart from the diffuse midline glioma, H3 K27 M-mutant, another muta-
tion present in the same gene, but in the G34 rather than the K27 position, defines another 
entity usually encountered in youths. The location differs, as it is no longer situated in the 
midline area, but in the brain hemispheres. High-grade astrocytic pediatric tumors with a tel-
encephalic location show the TP53, CDK2A, ATRX, and SETD2 mutations [164]. The genetic 
syndromes that favor the onset of brain tumors during childhood are type 1 neurofibromato-
sis and Li-Fraumeni syndrome.
4. Conclusions
The 2016 brain tumor classification represents an important step forward in the introduction 
of molecular diagnosis in the daily current practice. This is also an important step toward a 
personalized patient-tailored multimodal management of brain tumors. Neurosurgeons, as 
part of a multidisciplinary team, need to be familiarized with all the aspects regarding specific 
brain tumors in order to offer the best chance to their patients and to prolong survival with a 
good quality of life.
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Abbreviations
1p/19q-codel 1p/19q-codeleted
ATRX alpha thalassemia/mental retardation syndrome X-linked
CK cytokeratin
DA diffuse astrocytoma
DTI diffusion tensor images
EGFR epidermal growth factor receptor
EMA epithelial membrane antigen
FGFR1 fibroblast growth factor receptor 1
GBM glioblastoma
GFAP glial fibrillary acidic protein
HIF1A hypoxia-inducible factor 1-alpha
IDH isocitrate dehydrogenase
IDH-mut IDH-mutant
LT lymphocyte B
LT lymphocyte T
MDM2 mouse double minute 2 homolog
MDM4 mouse double minute 4
MGMT O6-methylguanine DNA methyltransferase
MRI magnetic resonance imaging
MRS magnetic resonance spectroscopy
ms milliseconds
NCAM1 neural cell adhesion molecule
NF1 neurofibromatosis 1
NOS not other specified
PI3K phosphatidylinositol-3 kinase
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PRESS spectra point-resolved spectroscopy
PTEN phosphatase and tensin homolog
Rb retinoblastoma
TE echo time
TERT telomerase reverse transcriptase
TP53 tumor protein
VEGFA vascular endothelial growth factor A
wt wild type
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